13 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 13 of 13 clinical reviews.
AndroGel raises red blood cell counts in a subset of men on TRT. Learn why it happens, how to manage hematocrit on testosterone gel, and which alternatives carry lower erythrocytosis risk.
Learn why AndroGel raises red blood cell counts, the step-by-step mechanism from EPO suppression to marrow stimulation, how often it occurs, and what your clinician can do to manage it safely.
Learn the warning signs of erythrocytosis from AndroGel testosterone gel, when to seek medical attention, why testosterone raises red blood cells, and how clinicians manage elevated hematocrit on TRT.
A clinical grading rubric for erythrocytosis caused by AndroGel (testosterone topical), including hematocrit thresholds, management protocols, and when to discontinue TRT.
AndroGel raises hematocrit in some men, and for a subset that elevation persists despite dose cuts or gel discontinuation. This guide explains why it happens, how long it lasts, and what your clinician should do next.
Evidence-based review of supplements that may help manage erythrocytosis during AndroGel (testosterone topical) therapy, including omega-3s, naringin, IP6, and curcumin.
Evidence-based dietary strategies to lower hematocrit and manage erythrocytosis caused by AndroGel testosterone gel, including hydration, iron modification, grapefruit naringin, omega-3s, and phlebotomy-sparing nutrition protocols.
How often does AndroGel raise hematocrit to concerning levels, who is most at risk, and what does clinical management actually look like? Evidence-anchored answers for patients and prescribers.
A phase-by-phase clinical timeline of testosterone-induced erythrocytosis on AndroGel: when hematocrit rises, when it peaks, when it resolves, and what the trial data say about each stage.
A clinician-grade, step-by-step protocol for assessing and managing erythrocytosis in patients using AndroGel (testosterone topical gel), including hematocrit thresholds, dose adjustment ladders, therapeutic phlebotomy criteria, and discontinuation triggers.
A clinical deep-dive on how slowing titration, pausing, stepping down, or microdosing AndroGel can bring hematocrit back into range, with real protocols and clear escalation thresholds.
Exact hematocrit thresholds, lab timelines, quality-of-life warning signs, and switching options for patients and prescribers managing erythrocytosis on AndroGel.
A clinical-grade explanation of how AndroGel (testosterone topical) triggers erythrocytosis, why the effect is milder than injectable testosterone, and what patients and prescribers can do about a rising hematocrit right now.